YOLFTbeta
ValiRx plc

ValiRx plc

VAL · LSE · Healthcare / Biotechnology

0.155GBX-0.01 (-3.13%)

Price History

Full chart

Market Stats

Previous Close0.16
Open0.15
Day Range0.15 – 0.1559
52-Week Range0.12 – 0.55
Volume1.26M
Market Cap1.78M
P/E (TTM)0.00
Forward P/E0.00
EPS0.00
Dividend Yield0.00%
Beta-0.24
50-Day Avg0.1472
200-Day Avg0.2405

About

ValiRx plc, together with its subsidiaries, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL401, a reformulation of anti-psychotic drug risperidone, which completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer; VAL201, a short peptide, which completed Phase I/II clinical trial for the treatment of prostate cancer; and VAL301, a peptide, which is in pre-clinical trial for the treatment of endometriosis. It is also involved in the development of BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment of SARS-CoV2 infection; and CLX001, a peptide in a nanoparticle formulation for the treatment of triple negative breast cancer. The company was founded in 2006 and is based in London, the United Kingdom.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Mark Edward Eccleston M.B.A., Ph.D.
  • Employees11
  • Headquarters20 Wenlock Road, London, United Kingdom, N1 7GU, UK
  • Websitehttps://valirx.com

Leadership

  • Dr. Mark Edward Eccleston M.B.A., Ph.D.CEO, Member of Scientific & Commercial Advisory Board and Director · b. 1971
  • Mr. James Gerry Desler FCACFO, Company Secretary & Executive Director · b. 1945
  • Mr. Kumar NawaniHead of Operations
  • Mr. Mark TreharneCorporate Development Manager
  • Dr. Andrew CarnegieHead of Strategic Commercial Development

Financials

Income Statement

Currency: GBP2001-12-312002-12-312003-12-312004-12-312005-12-312006-03-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue991.00K17.00K----12.77K42.00K31.00K8.00K177.00K455.00K216.27K124.87K87.56K82.60K00000009.60K49.77K31.37K
Growth (%)--98.28%-----+228.92%-26.19%-74.19%+2112.50%+157.06%-52.47%-42.26%-29.88%-5.66%-100.00%-------+418.49%-36.97%
Cost of Revenue380.00K-----12.77K--3.00K56.00K27.00K72.96K51.62K61.02K77.88K102.83K187.69K142.99K182.81K229.50K228.79K224.27K255.64K267.00K37.62K
Gross Profit611.00K17.00K-----42.00K31.00K5.00K121.00K428.00K143.31K73.25K26.53K4.73K-102.83K-187.69K-142.99K-182.81K-229.50K-228.79K-224.27K-246.04K-217.22K-6.25K
Gross Margin61.65%100.00%-----100.00%100.00%62.50%68.36%94.07%66.26%58.66%30.30%5.72%--------2562.95%-436.41%-19.92%
Operating Expense6.71M2.85M------41.00K1.25M1.03M576.00K1.49M2.49M2.98M3.16M3.03M4.07M2.94M3.72M2.52M1.42M1.45M2.37M2.05M1.92M1.82M
Operating Income-6.10M-2.84M-86.00K-345.00K-134.00K-64.00K-351.62K83.00K-1.22M-1.02M-455.00K-1.06M-2.35M-2.91M-3.14M-3.03M-4.17M-3.13M-3.87M-2.70M-1.65M-1.68M-2.59M-2.30M-2.14M-1.82M
Operating Margin-615.64%-16688.24%-----2753.69%197.62%-3938.71%-12762.50%-257.06%-233.63%-1086.09%-2331.33%-3584.06%-3667.43%--------23943.11%-4302.70%-5809.21%
EBITDA-5.22M-2.80M-86.00K-345.00K-134.00K-62.00K-415.33K-368.00K-1.87M-1.24M-431.00K-1.03M-2.27M-2.84M-3.55M-2.14M-5.31M-2.92M-4.69M-2.30M-1.31M-1.45M-2.37M-2.04M-1.86M-2.18M
EBITDA Margin-526.74%-16488.24%-----3252.67%-876.19%-6021.21%-15450.00%-243.50%-226.62%-1051.72%-2278.05%-4054.59%-2587.10%--------21295.17%-3741.20%-6939.28%
Net Income-5.48M-2.86M-150.00K-345.00K-134.00K-63.00K-382.61K-1.24M-1.86M-1.44M134.00K-933.00K-2.16M-2.60M-3.16M-2.12M-4.75M-3.14M-4.37M-2.43M-1.47M-1.55M-2.41M-2.04M-1.92M-2.23M
Net Income Margin-552.88%-16817.65%-----2996.38%-2952.38%-5987.10%-18037.50%75.71%-205.05%-1000.58%-2079.99%-3609.07%-2564.48%--------21226.05%-3848.71%-7115.13%
R&D-------156.00K146.00K73.00K120.00K420.00K1.01M1.62M1.77M1.54M2.38M1.75M1.70M984.46K230.12K303.79K551.23K383.36K245.16K229.38K
R&D as % of Total Revenue-------371.43%470.97%912.50%67.80%92.31%467.23%1299.28%2024.19%1868.50%-------3993.35%492.54%731.16%
Interest Expense597.00K064.00K00065.331.37M3.00K3.00K8.00K1.00K211801.53K1.79K338.19K449.87K14.56K21.18K14.88K2.77K5.46K4.42K1.28K3.33K
Interest Expense % of Total Revenue60.24%0.00%----0.51%3269.05%9.68%37.50%4.52%0.22%0.01%0.14%1.75%2.17%-------46.03%2.57%10.61%

Balance Sheet

Currency: GBP2001-12-312002-12-312003-12-312004-12-312005-12-312006-03-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets1.61M202.00K126.00K21.00K2.00K170.00K2.79M1.77M1.78M1.67M2.50M4.57M5.30M4.11M3.62M5.12M4.96M4.94M4.23M3.60M4.94M3.52M3.98M3.13M4.26M2.63M
Total Liabilities609.00K343.00K59.00K90.00K205.00K9.00K105.00K97.00K409.00K758.00K503.00K141.00K261.63K876.10K835.08K588.55K2.59M1.78M1.20M1.38M182.40K109.56K149.65K226.51K346.41K235.10K
Total Equity1.02M-141.00K67.00K-69.00K-203.00K-2.65M1.69M1.37M907.00K2.00M4.42M5.04M3.23M2.76M4.45M2.35M3.18M3.12M2.35M4.91M3.60M4.05M3.22M4.32M2.86M
Cash728.00K1.00K119.00K14.00K1.00K34.00K810.00K88.00K15.00K15.00K108.00K1.63M2.26M960.27K452.82K232.47K560.76K701.41K372.87K01.85M593.67K1.14M174.68K1.56M791.61K
Total Debt-------3.00K20.00K46.00K------1.29M390.12K313.70K199.41K71.06K58.72K37.71K22.07K11.86K1.40K
Net Debt-728.00K-1.00K-119.00K-14.00K-1.00K-34.00K-810.00K-85.00K5.00K31.00K-108.00K-1.63M-2.26M-960.27K-452.82K-232.47K733.54K-311.29K-59.17K199.41K-1.78M-534.95K-1.10M-152.61K-1.54M-790.22K

Cash Flow

Currency: GBP2001-12-312002-12-312003-12-312004-12-312005-12-312006-03-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow1.91M1.77M74.00K-225.00K-63.00K-55.00K-45.77K-839.00K-794.00K-926.00K-496.00K-1.46M-1.98M-2.07M-3.01M-2.59M-4.22M-2.35M-3.35M-1.34M-1.91M-1.26M-1.71M-1.77M-1.58M-1.51M
Investing Cash Flow-1.27M-234.00K----1.09M-122.00K-114.00K-70.00K-69.00K-193.00K-134.19K-128.69K62.13K-311.33K635.46K-206.24K-324.03K-250.26K-91.29K---306.18K-38.16K-13.58K
Financing Cash Flow-228.00K195.00K120.00K50.00K125.00K-264.53K239.00K819.00K969.00K701.00K3.18M2.74M895.83K2.44M2.68M3.91M2.70M3.35M1.21M3.85M7.34K2.26M1.12M3.00M759.35K
Capital Expenditure36.00K27.00K00041.00K5.02K135.00K87.00K70.00K141.00K202.00K134.19K134.06K275.25K421.60K386.63K280.33K324.03K396.78K93.29K25306.18K38.16K13.58K
Free Cash Flow1.87M1.74M74.00K-225.00K-63.00K-96.00K-50.79K-974.00K-881.00K-996.00K-637.00K-1.66M-2.11M-2.20M-3.28M-3.01M-4.60M-2.63M-3.68M-1.74M-2.00M-1.26M-1.71M-2.08M-1.62M-1.52M
FCF to OCF98.11%98.47%100.00%100.00%100.00%174.55%110.98%116.09%110.96%107.56%128.43%113.83%106.78%106.48%109.15%116.28%109.17%111.92%109.66%129.57%104.88%100.00%100.00%117.28%102.41%100.90%

Key Statistics & Ratios

Market Cap1.78M
Enterprise Value745.83K
Trailing P/E0.00
Forward P/E0.00
PEG Ratio0.00
Price / Sales54.55
Price / Book0.55
EPS0.00
Book Value0.004
Revenue (TTM)32.67K
Gross Profit (TTM)-4.95K
EBITDA-1.49M
Profit Margin0.00%
Operating Margin-63185.85%
Return on Equity-77.28%
Return on Assets-36.45%
Shares Outstanding1.32B
Shares Float789.47M
Beta-0.24
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Apr 6, 20201:125
  • May 18, 20151:125
  • Jul 31, 20071:30
  • Oct 3, 20061:2
  • Oct 21, 20031:100
  • Jan 7, 20021:10